Related Experiment Video
Updated: Mar 29, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Effectiveness of Maternal Respiratory Syncytial Virus Vaccination in Conferring Infant Immunity: Review and Future
Masatoki Kaneko1,2, Junsuke Muraoka1
1Department of Obstetrics and Gynecology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
Insights
Respiratory syncytial virus (RSV) causes severe infant infections. Antibody-based strategies, including vaccines and maternal immunization, are crucial for preventing RSV, with the F glycoprotein as a key target.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Respiratory syncytial virus (RSV) is a major cause of infant respiratory illness globally.
- Natural immunity to RSV is not durable, leading to reinfections and severe early-life disease.
- Current preventive strategies face challenges in providing long-term protection.
Purpose of the Study:
- To review antibody-mediated prevention of RSV infection.
- To evaluate vaccine development and maternal immunization strategies for RSV.
- To analyze RSV pathogenesis, immune evasion, and antigenic characteristics for vaccine design.
Main Methods:
- Review of current evidence on RSV pathogenesis and immune evasion.
- Focus on viral surface glycoproteins, particularly the F protein, as targets.
- Evaluation of licensed vaccines, monoclonal antibodies, and maternal immunization data.
Main Results:
- The RSV fusion (F) glycoprotein is the primary target for neutralizing antibodies and current interventions.
- The F protein shows constrained evolution, maintaining intervention effectiveness despite antigenic drift in other proteins.
- Waning antibody titers necessitate ongoing passive immunization strategies for infants.
Conclusions:
- Maternal vaccination and long-acting monoclonal antibodies are significant advances in infant RSV protection.
- Equitable global access to these interventions remains a challenge.
- Continued monitoring of viral evolution and antibody durability is essential for optimizing immunization strategies.
Abstract:
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection in infants and young children worldwide and continues to impose a substantial disease burden despite recent advances in preventive strategies. Natural infection does not confer durable protective immunity, resulting in repeated reinfections, with the most severe disease occurring during early infancy. This review examines antibody-mediated prevention of RSV infection, with particular emphasis on vaccine development and maternal immunization. We reviewed current evidence on RSV pathogenesis, immune evasion, and antigenic characteristics relevant to vaccine design, focusing on viral surface glycoproteins targeted by preventive strategies. Recent data on licensed vaccines, long-acting monoclonal antibodies, and maternal immunization approaches were also evaluated. The RSV fusion (F) glycoprotein is the principal target of neutralizing antibodies and underpins currently licensed vaccines and monoclonal antibody products. Although circulating RSV strains show gradual antigenic evolution, primarily in the attachment protein, the F protein remains relatively conserved, resulting in only modest reductions in neutralization by human polyclonal sera over time. Constrained evolution of the F protein likely contributes to the sustained effectiveness of F-based interventions. However, waning F-specific neutralizing antibody titers contribute to susceptibility to reinfection, underscoring the importance of passive immunization strategies during early life. Maternal vaccination and long-acting monoclonal antibodies represent key advances in protecting young infants against RSV, but challenges remain in achieving equitable global implementation. Continued evaluation of antigenic evolution, the durability of protection, and optimization of maternal and infant immunization strategies will be critical for long-term disease control.
More Related Videos
Related Concept Videos
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Vaccinations
Active versus Passive Immunity
Active Immunity
Active immunity refers to the resistance one develops...
Cytomegalovirus Disease
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Vaccines

